New insights from KOLs and management regarding centrally vs peripherally-driven CB1 inhibition, and data from Skye’s diet-induced obesity model highlighting dose-dependent weight loss.
KOL and management insights into the unmet treatment needs related to obesity, and the potential role of CB1 inhibition.